tada, thank you, The data showed remarkable results in reducing inflamed protein biomarkers in patients.

Do we know how many doses of ABL are needed to reduce ACE2 receptors with Type 2?  Complete coverage. How long the effect remains?  Appears ABL is very effective.  Just looking at the effectiveness of ABL in Type 2 patient acquiring COVID.  Some may not have that much time.  

Hopefully the tests have started.  How can one monitor or compare between groups the effectiveness when most COVID patients have different degrees of illness?

Not a scientist, just too many questions.  Thank you all.  This could be RVX's big break. sidebar